Antiangiogenic Effects of Axitinib, an Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinase, on Laser-Induced Choroidal Neovascularization in Mice

REFERENCES

• Amin R, Puklin JE, Frank RN. Growth factor localization in choroidal neovascular membranes of age-related macular degeneration. Invest Ophthalmol Vis Sci 1994;35:3178–3188.
   PubMed Web of Science ®Google Scholar
• Funk M, Karl D, Georgopoulos M, Benesch T, Sacu S, Polak K et al. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab. Ophthalmology 2009;116:2393–2399.
   PubMed Web of Science ®Google Scholar
• Lambooij AC, van Wely KH, Lindenbergh-Kortleve DJ, Kuijpers RW, Kliffen M, Mooy CM. Insulin-like growth factor-I and its receptor in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2003;44:2192–2198.
   PubMed Web of Science ®Google Scholar
• Ishibashi T, Hata Y, Yoshikawa H et al. Expression of vascular endothelial growth factor in experimental choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 1997;235:159–167.
   PubMed Web of Science ®Google Scholar
• Achen MG, Jeltsch M, Kukk E, Nakagawa K, Sueishi K, Inomata H. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA 1998;95:548–553.
   PubMed Web of Science ®Google Scholar
• Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 1994;269:26988–26995.
   PubMed Web of Science ®Google Scholar
• Takahashi T, Ueno H, Shibuya M. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene 1999;18:2221–2230.
   PubMed Web of Science ®Google Scholar
• Takahashi T, Yamaguchi S, Chida K, Shibuya M. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. EMBO J 2001;20:2768–2778.
   PubMed Web of Science ®Google Scholar
• Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998;273:30336–30343.
   PubMed Web of Science ®Google Scholar
• Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999;399:597–601.
   PubMed Web of Science ®Google Scholar
• Rousseau S, Houle F, Landry J, Huot J. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene 1997;15:2169–2177.
   PubMed Web of Science ®Google Scholar
• Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 2008;14:7272–7283.
   PubMed Web of Science ®Google Scholar
• Liu G, Rugo HS, Wilding G, Evelhoch JL, Ng C, Jackson E, Kelcz F et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol 2005;23:5464–5473.
   PubMed Web of Science ®Google Scholar
• Wilmes LJ, Pallavicini MG, Fleming LM, Gibbs J, Wang D, Li KL et al. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Imaging 2007;25:319–327.
   PubMed Web of Science ®Google Scholar
• Nakahara T, Norberg SM, Shalinsky DR, Hu-Lowe DD, McDonald DM. Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors. Cancer Res 2006;66:1434–1445.
   PubMed Web of Science ®Google Scholar
• Yafai Y, Yang XM, Niemeyer M, Nishiwaki A, Lange J, Wiedemann P et al. Anti-angiogenic effects of the receptor tyrosine kinase inhibitor, pazopanib, on choroidal neovascularization in rats. Eur J Pharmacol 2011;666:12–18.
   Google Scholar
• Tobe T, Okamoto N, Vinores MA, Derevjanik NL, Vinores SA, Zack DJ et al. Evolution of neovascularization in mice with overexpression of vascular endothelial growth factor in photoreceptors. Invest Ophthalmol Vis Sci 1998;39:180–188.
   PubMed Web of Science ®Google Scholar
• Campos M, Amaral J, Becerra SP, Fariss RN. A novel imaging technique for experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 2006;47:5163–5170.
   Google Scholar
• Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 2007;8:975–984.
   PubMed Web of Science ®Google Scholar
• Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008;26:4708–4713.
   PubMed Web of Science ®Google Scholar
• Schiller JH, Larson T, Ou SH, Limentani S, Sandler A, Vokes E et al. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. J Clin Oncol 2009;27:3836–3841.
   PubMed Web of Science ®Google Scholar
• Kernt M, Staehler M, Stief C, Kampik A, Neubauer AS. Resolution of macular oedema in occult choroidal neovascularization under oral Sorafenib treatment. Acta Ophthalmol 2008;86:456–458.
   PubMed Web of Science ®Google Scholar
• Diago T, Pulido JS, Molina JR, Collet LC, Link TP, Ryan EH Jr. Ranibizumab combined with low-dose sorafenib for exudative age-related macular degeneration. Mayo Clin Proc 2008;83:231–234.
   PubMed Web of Science ®Google Scholar
• Safety and efficacy of eral PTK787 in Patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD) (ADVANCE). Available at: http://www.clinicaltrials.gov/ct2/show/NCT00138632?order=1
   Google Scholar
• A study to evaluate the pharmacodynamics, safety, and pharmacokinetics of pazopanib drops in adult subjects with neovascular AMD. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00612456?order=1
   Google Scholar
• CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897–1908.
   Google Scholar
• Lux A, Llacer H, Heussen FM, Joussen AM. Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions. Br J Ophthalmol 2007;91:1318–1322.
   PubMed Web of Science ®Google Scholar
• Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT et al. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 2004;56:549–580.
   PubMed Web of Science ®Google Scholar
• Jo N, Mailhos C, Ju M, Cheung E, Bradley J, Nishijima K et al. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol 2006;168:2036–2053.
   PubMed Web of Science ®Google Scholar
• Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111:1287–1295.
   PubMed Web of Science ®Google Scholar
• Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes HP et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004;18:338–340.
   PubMed Web of Science ®Google Scholar